Building on these results, two phase 3 trials further validated selpercatinib’s clinical benefits: The LIBRETTO-431 trial (NCT04194944) established selpercatinib as a frontline therapy for RET fusion-positive NSCLC, while the LIBRETTO-531 trial (NCT04211337), the first randomized study to compare selpercatinib with multikinase inhibitors, reinforced its efficacy in treating RET-mutated MTC3,4. The gene discussed is RET; the disease is non-small cell lung carcinoma.